CN105377271A - 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 - Google Patents

含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 Download PDF

Info

Publication number
CN105377271A
CN105377271A CN201480028372.3A CN201480028372A CN105377271A CN 105377271 A CN105377271 A CN 105377271A CN 201480028372 A CN201480028372 A CN 201480028372A CN 105377271 A CN105377271 A CN 105377271A
Authority
CN
China
Prior art keywords
selenium
compositions
subject
expression
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028372.3A
Other languages
English (en)
Chinese (zh)
Inventor
R.鲍威尔
C.伊根
A.伊安尼库里斯
兰子鉴
肖日进
L.C.杰克逊
S.奎亚特科夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Priority to CN202210387608.9A priority Critical patent/CN114984038A/zh
Priority to CN202210024252.2A priority patent/CN114533753A/zh
Publication of CN105377271A publication Critical patent/CN105377271A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480028372.3A 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 Pending CN105377271A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210387608.9A CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210024252.2A CN114533753A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210024252.2A Division CN114533753A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210387608.9A Division CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Publications (1)

Publication Number Publication Date
CN105377271A true CN105377271A (zh) 2016-03-02

Family

ID=51537786

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480028372.3A Pending CN105377271A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210387608.9A Pending CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210024252.2A Pending CN114533753A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210387608.9A Pending CN114984038A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
CN202210024252.2A Pending CN114533753A (zh) 2013-03-15 2014-03-14 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用

Country Status (15)

Country Link
US (1) US9833486B2 (enExample)
EP (1) EP2968404B1 (enExample)
JP (1) JP6313418B2 (enExample)
KR (1) KR102245702B1 (enExample)
CN (3) CN105377271A (enExample)
AU (1) AU2014228785B2 (enExample)
BR (1) BR112015022514A2 (enExample)
CA (1) CA2903845C (enExample)
CL (1) CL2015002677A1 (enExample)
HK (1) HK1216506A1 (enExample)
MX (1) MX359626B (enExample)
RU (1) RU2663127C2 (enExample)
SG (2) SG10202101918RA (enExample)
WO (1) WO2014144776A1 (enExample)
ZA (1) ZA201506759B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456658A (zh) * 2014-03-14 2017-02-22 全技术公司 硒有机化合物的组合物和其使用方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
WO2020173172A1 (zh) * 2019-02-27 2020-09-03 高美雯 减肥片的组成及其制备方法
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513712A (ja) 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
CA3090241C (en) * 2018-04-25 2023-03-28 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN115917310A (zh) * 2020-06-29 2023-04-04 百时美施贵宝公司 用于分析来自生物反应器的样品的自动化系统和方法
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN101073584A (zh) * 2005-10-14 2007-11-21 全面技术公司 改变细胞功能的方法和组合物
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
CN101579355A (zh) * 2009-05-27 2009-11-18 徐建兴 一种维护线粒体功能的营养组合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
WO2004107881A1 (en) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008144543A2 (en) * 2007-05-18 2008-11-27 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
CA2694928A1 (en) * 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
BRPI0818007A2 (pt) * 2007-10-16 2015-11-03 Exichol Sa composição para regular o metabolismo lipídico
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
US8575320B2 (en) 2010-03-18 2013-11-05 Alltech, Inc. Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins
US8883498B2 (en) * 2010-04-22 2014-11-11 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN101073584A (zh) * 2005-10-14 2007-11-21 全面技术公司 改变细胞功能的方法和组合物
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
CN101579355A (zh) * 2009-05-27 2009-11-18 徐建兴 一种维护线粒体功能的营养组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOSHIHIKO KITAJIMA，ET AL: "Cytotoxic Mechanism of Selenomethionine in Yeast", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456658A (zh) * 2014-03-14 2017-02-22 全技术公司 硒有机化合物的组合物和其使用方法
WO2020173172A1 (zh) * 2019-02-27 2020-09-03 高美雯 减肥片的组成及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法

Also Published As

Publication number Publication date
US9833486B2 (en) 2017-12-05
CL2015002677A1 (es) 2016-12-09
CN114984038A (zh) 2022-09-02
BR112015022514A2 (pt) 2017-07-18
SG11201507061XA (en) 2015-10-29
WO2014144776A1 (en) 2014-09-18
AU2014228785B2 (en) 2018-01-25
NZ711842A (en) 2021-04-30
MX2015013275A (es) 2015-12-11
JP2016516058A (ja) 2016-06-02
CN114533753A (zh) 2022-05-27
JP6313418B2 (ja) 2018-04-18
EP2968404A1 (en) 2016-01-20
RU2015139742A (ru) 2017-04-21
MX359626B (es) 2018-10-01
RU2663127C2 (ru) 2018-08-01
SG10202101918RA (en) 2021-03-30
KR20150132374A (ko) 2015-11-25
CA2903845C (en) 2022-08-23
EP2968404B1 (en) 2026-07-22
HK1216506A1 (zh) 2016-11-18
CA2903845A1 (en) 2014-09-18
AU2014228785A1 (en) 2015-09-24
ZA201506759B (en) 2017-03-29
KR102245702B1 (ko) 2021-04-28
EP2968404A4 (en) 2017-01-04
US20160113977A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
AU2014228785B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Liu et al. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress
Sbodio et al. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities
Nettore et al. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats
JP6313479B2 (ja) 有機セレン化合物の組成物およびその使用方法
Ru et al. Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects
AU2010247734B2 (en) Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
Zhao et al. Regulation of cystathionine gamma-lyase/H2S system and its pathological implication
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
Xue et al. Nrf2 activation by pyrroloquinoline quinone inhibits natural aging‐related intervertebral disk degeneration in mice
Yu et al. Mechanisms of epigallocatechin gallate (EGCG) in ameliorating hyperuricemia: insights into gut microbiota and intestinal function in a mouse model
Lv et al. Ferroptosis in schizophrenia: Mechanisms and therapeutic potentials
Ren et al. Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota
Xu et al. Catalpol ameliorates dexamethasone-induced osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via the activation of PKD1 promoter
Ji et al. Apigenin alleviates dextran sulfate sodium-induced ulcerative colitis via regulation of endoplasmic reticulum stress in goblet cells
Liu et al. Medicago Sativa L. Saponin‐Driven Lactobacillus Intestinalis Restores Intestinal Stemness in Naturally Aged Mice via the Bile Acid‐FXR‐Wnt Signaling Axis
Jeong et al. β-Lapachone attenuates mitochondrial dysfunction in MELAS cybrid cells
Tu et al. Dietary administration of black raspberries modulates arsenic biotransformation and reduces urinary 8-oxo-2′-deoxyguanosine in mice
Xie et al. The yeast‐fermented garlic and a balance of spermine/spermidine activates autophagy via EGR1 transcriptional factor
Nagata et al. Protective effects of the alga fucoidan against amyloid-β-induced neurotoxicity in SH-SY5Y cells
US20230000888A1 (en) Nad-precursors and dietary restriction for treating age related medical conditions
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Li et al. Artemisiae Scopariae Herba (Yinchen) suppresses ferroptosis in mice with osteoporosis via the Nrf2/Slc7a11/Gpx4 pathway
Ahn et al. Unacylated Ghrelin Counteracts Contractile and Mitochondrial Dysfunction in Cancer Cachexia
Yang et al. Comprehensive analysis of yak milk residue peptides for anti-hypoxic functional foods: targeting neuroinflammation and apoptosis in hypoxic mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160302